CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: David Bajor, Ki Y Chung, James M Cleary, Ivan Diaz-Padilla, Catherine Ellis, Gerald Falchook, Srimoyee Ghosh, J Randolph Hecht, Richard Kim, Anuradha Krishnamurthy, Omkar Marathe, Jean-Marie Michot, Amita Patnaik, Shruti D Shah, Susanna Ulahannan, Judy Wang, Angela Waszak, Kaitlin Yablonski, Hagop Youssoufian, Hailei Zhang

Ngôn ngữ: eng

Ký hiệu phân loại:

Thông tin xuất bản: England : BJC reports , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 733285

 BACKGROUND: Dual programmed cell death protein (ligand)-1 (PD-[L]1) and lymphocyte-activation gene-3 (LAG-3) blockade has demonstrated improved anti-tumour response in some advanced solid tumours. CITRINO, a two-part, Phase 1 dose-escalation study, evaluated encelimab (TSR-033
  novel anti-LAG-3) monotherapy and in combination in patients with advanced/metastatic solid tumours. METHODS: Part 1 (P1) involved dose escalation (20-720 mg Q2W) of encelimab as monotherapy (P1A/B) and with dostarlimab (500 mg Q3W) in patients with previously treated advanced/metastatic solid tumours (P1C). P2 involved cohort expansion in patients with anti-PD-(L)1-naïve microsatellite stable advanced/metastatic colorectal cancer with recommended phase 2 dose (RP2D) of encelimab with dostarlimab as third/fourth-line therapy (P2A), or with dostarlimab, bevacizumab and mFOLFOX6/FOLFIRI as second-line therapy (P2B). Objectives included RP2D, safety/tolerability, efficacy, pharmacokinetics/pharmacodynamics, and exploratory biomarkers. RESULTS: Maximum tolerated encelimab dose was not reached
  720 mg Q2W was used for P2 plus dostarlimab 1000 mg Q6W. One dose-limiting toxicity occurred (Grade 2 myasthenia gravis
  P1A). No clinical responses were observed in P1
  1 (3%) and 4 (17%) patients achieved partial response in P2A and 2B, respectively. CONCLUSIONS: Encelimab has a manageable safety profile as a monotherapy and in tested combinations
  however, anti-tumour activity was limited. CLINICAL TRIAL REGISTRATION: NCT03250832.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH